FDA Counterfeiting Task Force Has Standardized Reporting In Its Sights
FDA's Counterfeit Drug Task Force interim report is expected to propose measures that would standardize how such drugs are reported to the agency
You may also be interested in...
FDA's public meeting on drug counterfeiting Oct. 15 will feature vendor displays of current anti-counterfeiting technology
An FDA task force could look to Florida's new drug wholesaler licensing requirements as a model that all states should adopt to combat counterfeiting
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011